Authors: Shruti Chopra, PhD | Vandana Yadav, MS | Stan Kachnowski, PhD, MPA
Vaginitis, encompassing bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), and trichomoniasis, affects millions of women globally, with high recurrence rates and limited long-term solutions from conventional drug therapies. BV accounts for 50% of vaginitis cases; VVC 20–25%. Almost 29% of
U.S. women aged 15-60 have BV at least once, with >50% recurrence within 6–12 months after standard antibiotic therapy. The annual global burden of VVC is projected to rise to 158 million cases by 2030…